The Adaptive Experience
Patients are receiving longer-term MRD monitoring with clonoSEQ.
For how long are patients monitored with clonoSEQ?
The significant growth in use of clonoSEQ over the past 1-2 years means that many clonoSEQ-tested patients are still in their first year or two of MRD monitoring. However, there is a growing cohort of patients who are being monitored longer-term. More than 1/3 of patients receiving a clonoSEQ MRD test in the past year have been monitored using clonoSEQ for more than 3 years.
Years after diagnosis that HCPs continue to assess MRD
This page is intended for use by healthcare professionals of the United States.
clonoSEQ® is available as a FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow samples from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) , and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers as a CLIA-validated laboratory developed test (LDT) service. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technicalsummary.